000121860 001__ 121860
000121860 005__ 20241125101127.0
000121860 0247_ $$2doi$$a10.3390/cancers15020329
000121860 0248_ $$2sideral$$a132236
000121860 037__ $$aART-2023-132236
000121860 041__ $$aeng
000121860 100__ $$aGascón-Ruiz, Marta
000121860 245__ $$aA Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer
000121860 260__ $$c2023
000121860 5060_ $$aAccess copy available to the general public$$fUnrestricted
000121860 5203_ $$a(1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3−CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3−CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56bright NK cell subpopulation (CD56+CD3−CD16−PD-1+) (p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size.
000121860 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000121860 590__ $$a4.5$$b2023
000121860 592__ $$a1.391$$b2023
000121860 591__ $$aONCOLOGY$$b78 / 322 = 0.242$$c2023$$dQ1$$eT1
000121860 593__ $$aOncology$$c2023$$dQ1
000121860 593__ $$aCancer Research$$c2023$$dQ2
000121860 594__ $$a8.0$$b2023
000121860 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000121860 700__ $$aRamírez-Labrada, Ariel
000121860 700__ $$aLastra, Rodrigo
000121860 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, Luis$$uUniversidad de Zaragoza
000121860 700__ $$0(orcid)0000-0002-9600-8116$$aPaño-Pardo, J. Ramón$$uUniversidad de Zaragoza
000121860 700__ $$aSesma, Andrea
000121860 700__ $$aZapata-García, María
000121860 700__ $$aMoratiel, Alba
000121860 700__ $$aQuílez, Elisa
000121860 700__ $$aTorres-Ramón, Irene
000121860 700__ $$aYubero, Alfonso
000121860 700__ $$aDomingo, María Pilar
000121860 700__ $$aEsteban, Patricia
000121860 700__ $$aGálvez, Eva M.
000121860 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000121860 700__ $$aIsla, Dolores
000121860 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000121860 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000121860 773__ $$g15, 2 (2023), 329 [19 pp.]$$pCancers$$tCancers$$x2072-6694
000121860 8564_ $$s1959841$$uhttps://zaguan.unizar.es/record/121860/files/texto_completo.pdf$$yVersión publicada
000121860 8564_ $$s2862357$$uhttps://zaguan.unizar.es/record/121860/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000121860 909CO $$ooai:zaguan.unizar.es:121860$$particulos$$pdriver
000121860 951__ $$a2024-11-22-11:57:56
000121860 980__ $$aARTICLE